July 23, 2020
Home » Press
MetVital, Inc. Announces FDA Fast Track Designation of Anhydrous Enol-Oxaloacetate (AEO) for the Treatment of Patients with Newly Diagnosed Glioblastoma Multiforme
June 18, 2020 – As seen in Biospace, San Diego Biotechnology Network, Targeted Oncology and more.
MetVital, Inc. Announces FDA Clearance of Investigational New Drug (IND) Application for AEO for Phase 2 testing for Glioblastoma Multiforme
June 11, 2019 – As seen in Business Insider, MarketWatch, Yahoo! Finance and more.